Skip to main content
A person holding a notebook speaks into a microphone

Industry Liaison Forum

The Industry Liaison Forum was established in 2001 to promote and facilitate the full contribution of the biomedical industry to the global HIV response. It does this by catalysing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum. Its members are from industry (originator and generic biopharmaceutical, diagnostic and other health-technology companies) and non-industry organizations. They share a wealth of perspectives, expertise and knowledge to contribute together to the HIV response.

The Forum’s strategic plan for 2020-2023 highlights its commitment to further build on its unique neutrality, convening power, multi-stakeholder composition and rules of engagement to strengthen its contribution to the HIV response. To achieve this, it:

  • Engages and grows membership by continuing to be a cross-stakeholder, neutral, safe-space platform that actively expands and engages its membership base to foster connections, dialogue and action.
  • Accelerates priority areas by addressing barriers along the HIV prevention, diagnosis and care continuum.
  • Publishes and promotes members’ perspectives to advance the global HIV response.

Interested in joining? Please contact [email protected].

Case Studies

Case study 1: Exploring long-acting solutions for mothers and newborns

In 2022, our roundtable discussions on long-acting technologies had a wide impact; over 5,100 participants accessed roundtable resources, and they led to two articles in the JIAS supplement, “Advancing LAED HIV prevention and treatment regimens”. As these technologies advance, the group identified a new challenge: meeting the specific needs of pregnant and breastfeeding people and newborns, particularly in resource-limited settings. The Forum’s session at IAS 2023, “Advancing HIV care for mothers and newborns through long-acting solutions”, addressed obstacles in developing and implementing long-acting HIV prevention and treatment options for mothers and newborns and shared experiences and best practices. The session drew 200 participants, generating remarkable engagement: 15,957 impressions and 406 interactions on social media.

alternative text

Case study 2: Reaching the 95-95-95 targets

The Forum brought together 200 virtual participants in a three-part roundtable series to explore challenges and solutions on industry’s contribution to achieving the 95 targets by 2025. Insights from these discussions led to the creation of a guidance document, “Key considerations to reach the 95-95-95 targets”, emphasizing the importance of collaboration, evidence-based interventions and focused strategies for industry, policy makers, healthcare professionals and community organizations involved in the global HIV response. The document is available here.

Photo © Isabel Corthier/MSF

alternative text

Case study 3: WHO Prequalification of In Vitro Diagnostics

In 2018, Forum industry partners published a perspective on World Health Organization (WHO) Prequalification of In Vitro Diagnostics in Clinical Infectious Diseases. In 2022, the Forum coordinated a roundtable discussion with representatives of regulatory and normative agencies, as well as the diagnostics and pharmaceutical industry, to introduce the newly published WHO collaborative procedure. This is a tool for national regulatory authorities that wish to enhance their pre-marketing and post-registration evaluation and registration of in vitro diagnostics. To access the roundtable materials, click here.

alternative text

Case study 4: The GAP-f

The Global Accelerator for Paediatric Formulations (GAP-f) resulted from collaboration between members of the Forum, the IAS Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) and WHO. Forum corporate partners working with international stakeholders steered the agenda and efforts to create GAP-f.

alternative text

Meet the Forum members

Co-chairs

Fernando Bognar
Fernando Bognar

Fernando Bognar

Vice President, Global Medical Affairs HIV, Gilead Sciences
United States
View
Nittaya Phanuphak
Nittaya Phanuphak

Nittaya Phanuphak

Institute of HIV Research and Innovation (IHRI)
Thailand
View

Civil Society members

Brent Allan
Brent Allan

Brent Allan

Global community engagement consultant
Australia
View
Rahab Mwaniki
Rahab Mwaniki

Rahab Mwaniki

Public Health Specialist and Programme Officer, National Empowerment Network of People Living with HIV/AIDS
Kenya
View
Wim Vandevelde
Wim Vandevelde

Wim Vandevelde

Liaison Officer, GNP+
South Africa
View

Industry members

Helen McDowell
Helen McDowell

Helen McDowell

Head of Government Affairs & Global Public Health, ViiV Healthcare
United Kingdom
View
James F Rooney
James F Rooney

James F Rooney

Gilead Sciences
United States
View
John Bannister
John Bannister

John Bannister

Vice President, Global Health, AccuBio
United Kingdom
View
Samuel (Tony) Boova
Samuel (Tony) Boova

Samuel (Tony) Boova

Director Alliance Development, High Burden HIV Global Markets, Beckman Coulter Life Sciences
United States
View
Silas Holland
Silas Holland

Silas Holland

Executive Director, Global Infectious Disease Policy, Merck
United States
View
Tisha Wheeler
Tisha Wheeler

Tisha Wheeler

Director, Global Health Policy, Roche Diagnostics
United States
View

Non-industry members

Anne Hoppe
Anne Hoppe

Anne Hoppe

Director, Innovation | Director, Geneva Office, Elizabeth Glaser Pediatric AIDS Foundation
Switzerland
View
Boniface Dongmo Nguimfack
Boniface Dongmo Nguimfack

Boniface Dongmo Nguimfack

Technical Lead Access to Medicines and Diagnostics, HIV, Hepatitis and STIs, HTM/HHS/SIA WHO
Switzerland
View
Carmen Pérez Casas
Carmen Pérez Casas

Carmen Pérez Casas

Senior Technical Manager, Strategy, Unitaid
Switzerland
View
Catherine Hankins
Catherine Hankins

Catherine Hankins

Amsterdam Institute for Global Health and Development (AIGHD)
Netherlands
View
Colleen Daniels
Colleen Daniels

Colleen Daniels

Deputy Director and Public Health Lead, Harm Reduction International
United Kingdom
View
Elliot P Cowan
Elliot P Cowan

Elliot P Cowan

Principal and Founder, Partners in Diagnostics. Chief Regulatory Officer, TestZone
United States
View
Ray Corrin
Ray Corrin

Ray Corrin

Prequalification of Medicines Program, World Health Organization, WHO
Switzerland
View
Sandeep Juneja
Sandeep Juneja

Sandeep Juneja

Senior Vice President of Market Access, TB Alliance
Switzerland
View
Sandra Nobre
Sandra Nobre

Sandra Nobre

Head of Business Development, Access to Medicines, Medicines Patent Pool
Switzerland
View
Yodit Belew
Yodit Belew

Yodit Belew

Associate Director for Therapeutics, Office of Infectious Disease, US Food and Drug Administration agency
United States
View

Ex-officio – International AIDS Society

Birgit Poniatowski
Birgit Poniatowski

Birgit Poniatowski

IAS Executive Director
International AIDS Society
Switzerland
View
Carole Beilleau
Carole Beilleau

Carole Beilleau

Director, Development and Partnerships
International AIDS Society
View
Jesse Giavina
Jesse Giavina

Jesse Giavina

Associate Officer, Resource Mobilization and Development
International AIDS Society
View
Julieta Firmat
Julieta Firmat

Julieta Firmat

Associate Officer, HIV Programmes & Advocacy
International AIDS Society
View
Nelli Barrière
Nelli Barrière

Nelli Barrière

Project Manager, HIV Programmes & Advocacy
International AIDS Society
View